Genetic testing pioneer 23andMe is looking at strategic alternatives, including a possible sale, it said Tuesday, months ...

23andMe CEO Anne Wojcicki sounded optimistic about the company's future during an earnings call in February last year. She said the biotech company, which offers direct-to-consumer genetic testing ...

By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...

"Management has determined that there is substantial doubt about the Company's ability to continue as a going concern," ...

From the San Francisco Business Times: Genetic testing pioneer 23andMe is looking at strategic alternatives, including a possible sale, it said Tuesday, months after co-founder and CEO Anne ...

23andMe faced major hurdles in 2024, including a $30 million settlement related to compromised data. 23andMe is now restructuring its business operations to reduce costs and streamline operations.

A 23andMe spokesperson said the company is "consistently focused on maintaining the privacy of our customers." 23andMe CEO Anne Wojcicki sounded optimistic about the company's future during an ...

The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations ...